Bicara therapeutics reports first quarter 2025 financial results and provides business update

Updated data from ongoing phase 1/1b trial in 1l r/m hnscc to be presented at 2025 asco annual meeting enrollment ongoing in fortifi-hn01, a pivotal phase 2/3 trial of ficerafusp alfa in 1l r/m hnscc strong financial position with approximately $462 million in cash and cash equivalents expected to fund operations into the first half of 2029 boston, may 13, 2025 (globe newswire) -- bicara therapeutics inc. (nasdaq: bcax), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced financial results for the first quarter ended march 31, 2025 and provided a business update. "we continued to execute across our clinical programs in the first quarter, maintaining strong momentum as we advance fortifi-hn01, the pivotal phase 2/3 trial of ficerafusp alfa in hpv-negative recurrent/metastatic head and neck squamous cell carcinoma," said claire mazumdar, phd, mba, chief executive officer of bicara therapeutics.
BCAX Ratings Summary
BCAX Quant Ranking